AP17A - Vaccine. - Google Patents

Vaccine. Download PDF

Info

Publication number: AP17A
Authority: AP; ARIPO
Prior art keywords: vector; protein; polypeptides; coli; polypeptide
Prior art date: 1985-02-07

Application number

APAP/P/1986/000020A

Other languages

English (en)

Other versions

AP8600020A0 (en

Inventor

Mitchell Stuart Gross

James Francis Young

Original Assignee

Smithkline Beckman Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-02-07

Filing date

1986-02-07

Publication date

1988-04-02

1986-02-01 Publication of AP8600020A0 publication Critical patent/AP8600020A0/xx

1986-02-07 Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp

1988-04-02 Application granted granted Critical

1988-04-02 Publication of AP17A publication Critical patent/AP17A/en

Links

229960005486 vaccine Drugs 0.000 title description 14
108090000623 proteins and genes Proteins 0.000 claims description 81
102000004169 proteins and genes Human genes 0.000 claims description 74
108090000765 processed proteins & peptides Proteins 0.000 claims description 69
102000004196 processed proteins & peptides Human genes 0.000 claims description 65
229920001184 polypeptide Polymers 0.000 claims description 63
241000588724 Escherichia coli Species 0.000 claims description 47
239000013598 vector Substances 0.000 claims description 22
108091026890 Coding region Proteins 0.000 claims description 21
239000013604 expression vector Substances 0.000 claims description 10
238000000034 method Methods 0.000 claims description 9
241000224016 Plasmodium Species 0.000 claims description 6
238000010438 heat treatment Methods 0.000 claims description 5
230000001105 regulatory effect Effects 0.000 claims description 5
102220006123 rs1042713 Human genes 0.000 claims description 5
239000006228 supernatant Substances 0.000 claims description 5
102220226324 rs1064794702 Human genes 0.000 claims description 3
102220045637 rs587782266 Human genes 0.000 claims description 3
108010077805 Bacterial Proteins Proteins 0.000 claims description 2
101000667595 Homo sapiens Ribonuclease pancreatic Proteins 0.000 claims description 2
101000726057 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 claims description 2
102100039832 Ribonuclease pancreatic Human genes 0.000 claims description 2
239000003599 detergent Substances 0.000 claims description 2
238000012258 culturing Methods 0.000 claims 1
102220278932 rs121913388 Human genes 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 71
210000003046 sporozoite Anatomy 0.000 description 30
239000012634 fragment Substances 0.000 description 27
239000013612 plasmid Substances 0.000 description 21
241000223960 Plasmodium falciparum Species 0.000 description 19
150000001413 amino acids Chemical group 0.000 description 18
235000001014 amino acid Nutrition 0.000 description 17
229940024606 amino acid Drugs 0.000 description 17
102100031675 DnaJ homolog subfamily C member 5 Human genes 0.000 description 15
239000000872 buffer Substances 0.000 description 14
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
239000002953 phosphate buffered saline Substances 0.000 description 13
108020004414 DNA Proteins 0.000 description 11
239000002671 adjuvant Substances 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
229940037003 alum Drugs 0.000 description 10
230000014509 gene expression Effects 0.000 description 10
230000009545 invasion Effects 0.000 description 10
239000002609 medium Substances 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
230000009257 reactivity Effects 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
101150106626 Ell gene Proteins 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000000203 mixture Substances 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 7
108020004705 Codon Proteins 0.000 description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
241000223801 Plasmodium knowlesi Species 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
238000010367 cloning Methods 0.000 description 6
241000894007 species Species 0.000 description 6
238000010186 staining Methods 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
101150061166 tetR gene Proteins 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
241000255925 Diptera Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
108020005038 Terminator Codon Proteins 0.000 description 4
239000004098 Tetracycline Substances 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
102200030043 rs10012 Human genes 0.000 description 4
230000007017 scission Effects 0.000 description 4
229960002180 tetracycline Drugs 0.000 description 4
229930101283 tetracycline Natural products 0.000 description 4
235000019364 tetracycline Nutrition 0.000 description 4
150000003522 tetracyclines Chemical class 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000224017 Plasmodium berghei Species 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
229940024545 aluminum hydroxide Drugs 0.000 description 3
238000009835 boiling Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
201000004792 malaria Diseases 0.000 description 3
239000000047 product Substances 0.000 description 3
210000003079 salivary gland Anatomy 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
101150052200 CS gene Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
241000223810 Plasmodium vivax Species 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000011210 chromatographic step Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
239000002502 liposome Substances 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
102220090143 rs758476299 Human genes 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
239000004475 Arginine Chemical group 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101100185024 Mus musculus Mslnl gene Proteins 0.000 description 1
101150033828 NS1 gene Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
241000223992 Plasmodium gallinaceum Species 0.000 description 1
241000223821 Plasmodium malariae Species 0.000 description 1
206010035501 Plasmodium malariae infection Diseases 0.000 description 1
241001505293 Plasmodium ovale Species 0.000 description 1
206010035502 Plasmodium ovale infection Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
125000004799 bromophenyl group Chemical group 0.000 description 1
244000309464 bull Species 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000009650 gentamicin protection assay Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
244000000056 intracellular parasite Species 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000005497 microtitration Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000008191 permeabilizing agent Substances 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
238000002135 phase contrast microscopy Methods 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Tropical Medicine & Parasitology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

APAP/P/1986/000020A 1985-02-07 1986-02-07 Vaccine. AP17A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US69911585A	1985-02-07	1985-02-07

Publications (2)

Publication Number	Publication Date
AP8600020A0 AP8600020A0 (en)	1986-02-01
AP17A true AP17A (en)	1988-04-02

Family

ID=24808000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1986/000020A AP17A (en)	1985-02-07	1986-02-07	Vaccine.

Country Status (19)

Country	Link
EP (1)	EP0191748B1 (ja)
JP (2)	JPH0698005B2 (ja)
CN (1)	CN86100979A (ja)
AP (1)	AP17A (ja)
AT (1)	ATE82322T1 (ja)
AU (1)	AU603054B2 (ja)
DE (1)	DE3687071T2 (ja)
DK (1)	DK62486A (ja)
EG (1)	EG17878A (ja)
ES (1)	ES8704975A1 (ja)
GR (1)	GR860351B (ja)
HU (1)	HU201803B (ja)
IL (1)	IL77788A0 (ja)
MY (1)	MY102249A (ja)
NZ (1)	NZ215034A (ja)
OA (1)	OA08199A (ja)
PT (1)	PT81967B (ja)
YU (1)	YU18186A (ja)
ZA (1)	ZA86797B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3686178T2 (de) *	1985-02-07	1993-03-11	Smithkline Beckman Corp	Malaria-impfstoff.
IT1187710B (it) *	1985-07-25	1987-12-23	Eniricerche Spa	Composizione peptidica utile per la preparazione di vaccini per la malaria e di kit diagnostici per la determinazione di affezioni malariche
EP0252588A3 (en) *	1986-05-12	1989-07-12	Smithkline Beecham Corporation	Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
EP0254862A1 (en) *	1986-06-26	1988-02-03	BEHRINGWERKE Aktiengesellschaft	Vaccines against protozoan parasites
AU612340B2 (en) *	1986-11-04	1991-07-11	Protein Polymers Technologies, Inc.	Construction of synthetic dna and its use in large polypeptide synthesis
IT1198225B (it) *	1986-12-04	1988-12-21	Eniricerche Spa	Polipeptidi immunologicamente attivi utili per la preparazione di vaccini antimalaria e di kits diagnostici per la determinazione di anticorpi antisporozoita
AP56A (en) *	1987-01-30	1989-09-26	Smithkline Biologicals S A	Hepatitis B virus surface antigens and hybrid antigehs containing them.
JPH0222300A (ja) *	1987-02-02	1990-01-25	Swiss Serum & Vaccine Inst Bern	免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
AT388934B (de) *	1987-11-13	1989-09-25	Wellcome Found	Rekombinationskonjugatprotein und neue vakzinen
ATE95188T1 (de) *	1987-12-23	1993-10-15	Immuno Ag	Zellulaere amphipatische proteine in aggregierten formen und verfahren zur herstellung und reinigung diese proteine.
CA2015722A1 (en) *	1989-05-03	1990-11-03	Mitchell S. Gross	Malaria vaccine
CA2031468A1 (en) *	1989-12-08	1991-06-09	Mitchell S. Gross	Malaria vaccine
US9119815B2 (en)	2009-05-05	2015-09-01	Cadila Healthcare Limited	Combined measles-malaria vaccine
US20180153945A1 (en) *	2016-12-05	2018-06-07	The United States Of America, As Represented By The Secretary Of Agriculture	Oral e. coli vector-based vaccine for prevention of coccidiosis in poultry

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2145092B (en) *	1983-01-28	1988-04-07	Univ New York	Protective peptide antigen
US4466917A (en) *	1981-02-12	1984-08-21	New York University	Malaria vaccine
AU569722B2 (en) *	1983-01-28	1988-02-18	Saramane Pty Ltd	Expression of plasmodium falciparum polypeptides from cloned cdna
WO1985003724A1 (en) *	1984-02-21	1985-08-29	National Research Development Corporation	Improvements in or relating to the production of malaria vaccines
US4707357A (en) *	1984-06-26	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Immunologically active peptides capable of inducing immunization against malaria and genes encoding therefor

1985
- 1985-02-07 CN CN198686100979A patent/CN86100979A/zh active Pending
1986
- 1986-02-03 DE DE8686870013T patent/DE3687071T2/de not_active Expired - Fee Related
- 1986-02-03 AU AU52936/86A patent/AU603054B2/en not_active Ceased
- 1986-02-03 AT AT86870013T patent/ATE82322T1/de not_active IP Right Cessation
- 1986-02-03 EP EP86870013A patent/EP0191748B1/en not_active Expired - Lifetime
- 1986-02-04 NZ NZ215034A patent/NZ215034A/xx unknown
- 1986-02-04 ZA ZA86797A patent/ZA86797B/xx unknown
- 1986-02-04 PT PT81967A patent/PT81967B/pt not_active IP Right Cessation
- 1986-02-04 IL IL77788A patent/IL77788A0/xx unknown
- 1986-02-05 ES ES551656A patent/ES8704975A1/es not_active Expired
- 1986-02-05 GR GR860351A patent/GR860351B/el unknown
- 1986-02-06 EG EG64/86A patent/EG17878A/xx active
- 1986-02-06 OA OA58779A patent/OA08199A/xx unknown
- 1986-02-06 JP JP61025660A patent/JPH0698005B2/ja not_active Expired - Lifetime
- 1986-02-06 HU HU86505A patent/HU201803B/hu not_active IP Right Cessation
- 1986-02-07 AP APAP/P/1986/000020A patent/AP17A/en active
- 1986-02-07 DK DK62486A patent/DK62486A/da not_active Application Discontinuation
- 1986-02-07 YU YU00181/86A patent/YU18186A/xx unknown
1987
- 1987-10-12 MY MYPI87002891A patent/MY102249A/en unknown
1994
- 1994-05-20 JP JP6106595A patent/JPH07102150B2/ja not_active Expired - Lifetime

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
none *

Also Published As

Publication number	Publication date
MY102249A (en)	1992-05-15
JPH0698005B2 (ja)	1994-12-07
EG17878A (en)	1991-06-30
GR860351B (en)	1986-06-05
DE3687071D1 (de)	1992-12-17
AP8600020A0 (en)	1986-02-01
DE3687071T2 (de)	1993-03-25
YU18186A (en)	1988-06-30
DK62486A (da)	1986-08-08
EP0191748A1 (en)	1986-08-20
ES8704975A1 (es)	1987-04-16
JPS61181387A (ja)	1986-08-14
PT81967B (pt)	1988-07-01
EP0191748B1 (en)	1992-11-11
ATE82322T1 (de)	1992-11-15
ZA86797B (en)	1986-09-24
CN86100979A (zh)	1986-12-17
HUT40917A (en)	1987-03-30
ES551656A0 (es)	1987-04-16
DK62486D0 (da)	1986-02-07
NZ215034A (en)	1989-07-27
OA08199A (en)	1987-10-30
AU5293686A (en)	1986-08-14
PT81967A (en)	1986-03-01
HU201803B (en)	1990-12-28
AU603054B2 (en)	1990-11-08
JPH07170995A (ja)	1995-07-11
JPH07102150B2 (ja)	1995-11-08
IL77788A0 (en)	1986-07-31

Publication	Publication Date	Title
US5726292A (en)	1998-03-10	Immuno-potentiating systems for preparation of immunogenic materials
AP17A (en)	1988-04-02	Vaccine.
AP18A (en)	1988-04-02	Vaccine.
US20110020387A1 (en)	2011-01-27	Malaria vaccine
JP2000506381A (ja)	2000-05-30	マラリア原虫ｍｓｐ―１のｃ末端断片を含む組換えタンパク質
AU656914B2 (en)	1995-02-23	New peptides and their use
AU634837B2 (en)	1993-03-04	Malaria vaccine
EP0398540A1 (en)	1990-11-22	Malaria vaccine
EP0254862A1 (en)	1988-02-03	Vaccines against protozoan parasites
Chen et al.	0	proteins are bound to the Ni"-chelated surface in a uniform
DD259877A5 (de)	1988-09-07	Verfahren zur Herstellung eines Polypeptids für die Prophylaxe von Plasmodium-Infektionen von Säugern
HK1080754B (en)	2009-12-24	Malaria vaccine
DD254958A5 (de)	1988-03-16	Verfahren zur Herstellung einer Transformante zur Expression eines immunogenen Polypeptids, das mit dem Cs-Protein von Plasmodien kreuzreagierende Antikörper induziert